EyePoint Pharmaceuticals Annual Revenue, Number of Employees, Growth and Funding

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$86M
Industry:Biotech
Founded:N/A
Lead Investor(s):CR Group L.P.
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • EyePoint Pharmaceuticals's estimated annual revenue is currently $3M per year.
  • EyePoint Pharmaceuticals received $60.0M in venture funding in February 2019.
  • EyePoint Pharmaceuticals's estimated revenue per employee is $28,748
  • EyePoint Pharmaceuticals's total funding is $86M.

Employee Data

  • EyePoint Pharmaceuticals has 103 Employees.
  • EyePoint Pharmaceuticals grew their employee count by 4% last year.
  • EyePoint Pharmaceuticals currently has 2 job openings.

Executive Contacts

NameTitle
Mark SchimpfHead Of Sales Operations
Chris FasanelloField Reimbursement Manager
Claudette GalvezSenior Quality Assurance Manager
Jack WeetSenior Vice President, Regulatory Affairs And Quality
Naomi NoriegaKey Account Manager
Tom BonkNational Business Director, Amplity Health
Juan HernandezKey Account Manager
Josh StultsSurgical Key Account Manager - Dexycu
Matt BurtonKey Account Manager
Carrie DonnellyKey Account Manager

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products. As a leading provider of miniaturized, sustained-release drug delivery products, we focus on improving the lives of patients with serious eye disorders in indications with high unmet medical need. With 3 FDA-approved sustained release treatments in ophthalmology we continue to push the evolution of our Durasert Technology platform to further enhance treatments for wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

103

Number of Employees

$3M

Revenue (est)

2

Current Jobs

4%

Employee Growth %

$86M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
$7.1M4659%N/A
Tango Therapeut...
$9M5841%N/A
Compass Therape...
$15.8M10215%N/A
Emulate
$14.7M95-17%N/A
Hamilton Storag...
$14.6M949%N/A
Alnylam Pharmac...
$74.9M122831%N/A
Axcella
$8.8M5719%N/A
Berkshire Corpo...
$11.5M7412%N/A
Repligen Corpor...
$50.2M32422%N/A
Allena Pharmace...
$6M5019%N/A

EyePoint Pharmaceuticals News

09/03/2019 - EyePoint Pharmaceuticals Announces Data Highlighting ...

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting ...

09/08/2019 - Short Interest in Eyepoint Pharmaceuticals Inc (NASDAQ ...

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the target of a significant increase in short interest during the month of July. As of July 31st, ...

09/03/2019 - What EyePoint Pharmaceuticals, Inc. ($EYPT) Traders Should ...

On its latest session, EyePoint Pharmaceuticals, Inc. ($EYPT) opened at 1.45, reaching a high of 1.55 and a low of 1.43 before closing at a ...

EyePoint Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2011-01-20$10.8MUndisclosedRodman & Renshaw LLCArticle
2012-08-03$5.4MUndisclosedRodman & Renshaw LLCArticle
2013-07-22$10.8MUndisclosedArticle
2014-03-14$7.0MUndisclosedRA CapitalArticle
2014-10-28$25.0MUndisclosedArticle
2019-02-14$60.0MUndisclosedCR Group L.P.Article

EyePoint Pharmaceuticals Executive Hires

DateNameTitleReference
2016-09-16Nancy LurkerCEOArticle
2018-08-02David PriceCFOArticle
2018-11-28Ron HonigSVP General Counsel & Company SecretaryArticle